Skip to content

Study · Animal study (in vivo) · mouse · 2021

6 results

LTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells.

Yamazaki T, Wennerberg E, Hensler M, Buqué A, Kraynak J, Fucikova J, Zhou XK, Sveinbjørnsson B, Rekdal Ø, Demaria S, Galluzzi L

Oncoimmunology10 Aug 2021Cited by 39 (Europe PMC)

PMID34408925 (opens in a new tab)PMCIDPMC8366543 (opens in a new tab)DOI10.1080/2162402x.2021.1962592 (opens in a new tab)PepBankPUB-34408925
Read at sourcePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study6

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mouse breast carcinoma models, LTX‑315 controlled breast cancer.

    In plain wordsIn mice, LTX‑315 controlled breast cancer.

    Peptide
    LTX-315
    Outcome
    DecreaseBreast cancer control
    Study

    mousen: not reported in source

    breast carcinoma
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · intratumoralAs given in this study (mouse).

    Source sentences

    Summary
    We found that breast cancer control by LTX-315 is accompanied by a reconfiguration of the immunological tumor microenvironment that supports the activation of anticancer immunity and can be boosted by radiation therapy.
    1 context sentence
    Summary · context
    Here, we investigated the therapeutic activity and immunological correlates of intratumoral LTX-315 administration in three syngeneic mouse models of breast carcinoma, with a focus on the identification of possible combinatorial partners.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In mouse breast carcinoma models, LTX‑315 reconfigured the tumor immune microenvironment to support anticancer immunity.

    In plain wordsIn mice, LTX‑315 changed the tumor environment to support anticancer immunity.

    Peptide
    LTX-315
    Outcome
    Not applicableTumor immune microenvironment
    Study

    mousen: not reported in source

    breast carcinoma
    Outcome group
    Immune response · Cancer
    Studied dose
    Dose not stated · intratumoralAs given in this study (mouse).

    Source sentences

    Summary
    We found that breast cancer control by LTX-315 is accompanied by a reconfiguration of the immunological tumor microenvironment that supports the activation of anticancer immunity and can be boosted by radiation therapy.
    1 context sentence
    Summary · context
    Here, we investigated the therapeutic activity and immunological correlates of intratumoral LTX-315 administration in three syngeneic mouse models of breast carcinoma, with a focus on the identification of possible combinatorial partners.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In mice with triple-negative breast cancer, NK-cell depletion compromised LTX‑315 control of local progression.

    In plain wordsIn mice, NK-cell depletion weakened local breast cancer control with LTX‑315.

    Peptide
    LTX-315
    Outcome
    DecreaseNK-dependent local disease control
    Study

    mousen: not reported in source

    breast carcinoma
    Comparator
    without NK-cell depletion
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · intratumoralAs given in this study (mouse).

    Source sentences

    Summary
    Mechanistically, depletion of natural killer (NK) cells compromised the capacity of LTX-315 to limit local and systemic disease progression in a mouse model of triple-negative breast cancer, and to extend the survival of mice bearing hormone-accelerated, carcinogen-driven endogenous mammary carcinomas.
    1 context sentence
    Summary · context
    Here, we investigated the therapeutic activity and immunological correlates of intratumoral LTX-315 administration in three syngeneic mouse models of breast carcinoma, with a focus on the identification of possible combinatorial partners.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In mice with triple-negative breast cancer, NK-cell depletion compromised LTX‑315 control of systemic progression.

    In plain wordsIn mice, NK-cell depletion weakened systemic breast cancer control with LTX‑315.

    Peptide
    LTX-315
    Outcome
    DecreaseNK-dependent systemic disease control
    Study

    mousen: not reported in source

    breast carcinoma
    Comparator
    without NK-cell depletion
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · intratumoralAs given in this study (mouse).

    Source sentences

    Summary
    Mechanistically, depletion of natural killer (NK) cells compromised the capacity of LTX-315 to limit local and systemic disease progression in a mouse model of triple-negative breast cancer, and to extend the survival of mice bearing hormone-accelerated, carcinogen-driven endogenous mammary carcinomas.
    1 context sentence
    Summary · context
    Here, we investigated the therapeutic activity and immunological correlates of intratumoral LTX-315 administration in three syngeneic mouse models of breast carcinoma, with a focus on the identification of possible combinatorial partners.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In mice with endogenous mammary carcinomas, NK-cell depletion compromised survival extension with LTX‑315.

    In plain wordsIn mice with mammary carcinomas, NK-cell depletion weakened survival extension with LTX‑315.

    Peptide
    LTX-315
    Outcome
    DecreaseNK-dependent survival extension
    Study

    mousen: not reported in source

    hormone-accelerated, carcinogen-driven endogenous mammary carcinomas
    Comparator
    without NK-cell depletion
    Outcome group
    Mortality · Cancer
    Studied dose
    Dose not stated · intratumoralAs given in this study (mouse).

    Source sentences

    Summary
    Mechanistically, depletion of natural killer (NK) cells compromised the capacity of LTX-315 to limit local and systemic disease progression in a mouse model of triple-negative breast cancer, and to extend the survival of mice bearing hormone-accelerated, carcinogen-driven endogenous mammary carcinomas.
    1 context sentence
    Summary · context
    Here, we investigated the therapeutic activity and immunological correlates of intratumoral LTX-315 administration in three syngeneic mouse models of breast carcinoma, with a focus on the identification of possible combinatorial partners.

Studies that did not test the peptide alone1

In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking LTX-315.

  1. 06AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Efficacy outcome

    In mouse breast carcinoma models, radiation therapy boosted cancer control with LTX‑315.

    In plain wordsIn mice, radiation therapy boosted cancer control with LTX‑315.

    Peptide
    LTX-315
    Outcome
    IncreaseRadiotherapy enhancement of cancer control
    Study

    mousen: not reported in source

    breast carcinoma
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    We found that breast cancer control by LTX-315 is accompanied by a reconfiguration of the immunological tumor microenvironment that supports the activation of anticancer immunity and can be boosted by radiation therapy.
    1 context sentence
    Summary · context
    Here, we investigated the therapeutic activity and immunological correlates of intratumoral LTX-315 administration in three syngeneic mouse models of breast carcinoma, with a focus on the identification of possible combinatorial partners.

    In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.